🔎 Trials Near Me

Beranda › Neuroblastoma › Pennsylvania

Uji klinis Neuroblastoma di Pennsylvania

14 studi untuk Neuroblastoma mencari peserta di lokasi di Pennsylvania.

Kota di Pennsylvania

Teks studi resmi (Bahasa Inggris)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Children's Hospital of Philadelphia, Philadelphia
  • dan 2 lainnya
Menerima pesertaFase 3
Hingga usia 30 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06172296

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
Menerima pesertaFase 1/2
6 Months – 25 Years · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06395103

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Menerima pesertaFase 2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT02559778

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Menerima pesertaFase 1/2
Hingga usia 26 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06465199

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Menerima pesertaFase 1/2
Hingga usia 30 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06541262

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Menerima pesertaFase 2
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06540963

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Lehigh Valley Hospital-Cedar Crest, Allentown
  • Geisinger Medical Center, Danville
  • Penn State Children's Hospital, Hershey
  • dan 2 lainnya
Menerima pesertaFase 3
365 Days – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Children's Hospital of Philadelphia, Philadelphia
  • Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Menerima pesertaFase 1/2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04851119

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

  • Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
Menerima pesertaFase 2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT05489887

SPEARHEAD-3 Pediatric Study

  • Children's Hospital of Philedephia, Philadelphia
Menerima pesertaFase 1/2
Usia 2 hingga 21 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05642455

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

  • Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 1/2
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06721689

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

  • Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaFase 2
Usia 1 hingga 31 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT06450041

Neuroblastoma Biology Study

  • Children's Hospital of Philadelphia, Philadelphia
Menerima pesertaStudi observasional
31 Days – 99 Years · Semua jenis kelamin · Diperbarui 23 Mar 2026 · NCT01587300

Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma

  • Children's Hospital of Philadelphia, Philadelphia
Menerima peserta
Hingga usia 17 · Semua jenis kelamin · Diperbarui 10 Feb 2026 · NCT06831552

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.